Changzhou Yinsheng Pharmaceutical Co., Ltd., Sichuan University and Wuxi Wuxi Pharmaceutical Co., Ltd. jointly develop a new drug of anti drug resistant tuberculosis

On May 17, Changzhou Yinsheng Pharmaceutical Co., Ltd signed a tripartite agreement with Sichuan University and Shanghai yaomingkant new drug development Co., Ltd to jointly develop a new drug resistant to tuberculosis, with a cooperation amount of 31 million yuan After the industrialization of the project, it is expected that the domestic sales value will be more than 5 billion yuan It is reported that this is the second time for the three units to work together The first-class hepatitis C new drug jointly developed by the three parties has been approved as a major science and technology special project of "12th Five Year Plan" and will be applied for clinical application this month Wei Yuquan, vice president of Sichuan University, Yan Li, Secretary of Changzhou municipal Party committee, Zhang Donghai, deputy director of the Municipal People's Congress, Secretary of the Party Working Committee of Changzhou high tech Zone, Zhang yunyun, deputy mayor, Jia Xiujuan, deputy director of the Management Committee of Changzhou high tech Zone attended the signing ceremony Yan Li, meeting with Wei Yuquan and his party, said that the biomedical industry is one of the top ten key industrial chains in Changzhou At present, 41 pharmaceutical manufacturers in the city have 787 drug registration approvals and 65 new drug certificates It is hoped that Sichuan University will continue to maintain a good cooperative relationship with Changzhou, expand more fields of cooperation, and have new achievements and put them into use in every stage This time, Changzhou Yinsheng Pharmaceutical Co., Ltd signed a contract with Sichuan University and Shanghai yaomingkant new drug development Co., Ltd to develop two new drugs of anti drug resistant tuberculosis The drug is a bactericide with a novel mode of action, which can interfere with the metabolism of the cell wall of Mycobacterium tuberculosis (MTB), directly kill drug-resistant tuberculosis and treat drug-resistant tuberculosis The drug has high fungicidal activity in vitro, including strains resistant to first-line antituberculotic drugs such as isoniazid and rifampicin More than 100 new compounds have been designed and synthesized by the three parties, and many of them show good activity It is expected that a more perfect compound will be obtained through the study of structure-activity relationship for about one year It is planned to declare the clinical application of the first compound by the end of 2016, and the clinical application of the second compound in June 2017 Finally, these two first-class new drugs will also In clinical, the combination of drugs, through the role of different targets to reduce side effects, shorten the treatment cycle After the two first-class new drugs are listed, the domestic sales value is expected to be more than 5 billion yuan, and the tax revenue will be more than 500 million yuan According to reports, in May 2012, Yinsheng pharmaceutical signed a contract with Sichuan University for the cooperative development of new hepatitis C drugs Later, it introduced Shanghai Pharmaceutical mingkant new drug development Co., Ltd to carry out three-way cooperation in the development of new hepatitis C drugs with two targets Wuxi apptec is one of the internationally recognized authorities in the research and development of new anti HCV drugs Through the efforts of the three parties in recent 3 years, fubitavir, the compound for clinical application, has been approved as a major special project of science and technology for "12th Five-Year plan" and "major new drug creation" The target compound has applied for two Chinese invention patents and two international PCT (patent cooperation agreement) patents In terms of clinical application, the compound has completed the process and quality research, pharmacodynamics and pharmacokinetics research, pharmaceutics research and safety evaluation test, and it is planned to apply for clinical application in May In addition, the compound "amphenicol" which was declared clinically also showed good in vitro activity The project has completed pharmacology, pharmacokinetics and pharmaceutics research, and GLP safety evaluation is currently in progress The compound has also applied for a Chinese invention patent and will apply for a PCT patent this year It is worth mentioning that the two kinds of compounds have the characteristics of very good combination of drugs, which can reduce the resistance of virus, shorten the treatment cycle and improve the efficacy of drugs From the data, the index is even larger than the best drugs on the market in the United States, and the treatment effect will reach the world's leading level After the two first-class new drugs are launched, the domestic sales value is expected to be more than 3 billion yuan, and the tax revenue will be more than 300 million yuan Changzhou Yinsheng Pharmaceutical Co., Ltd is located in Changzhou high tech Zone As a high-tech enterprise of high-end API production, the company's scientific and technological personnel account for 35% of the total number of employees It has 3 invention patents and applied for 5 Chinese invention patents and 2 PCT patents Among them, aminomethylbenzoic acid and aminomethylcyclophosphate have passed the GMP certification of the State Food and drug administration, and aminomethylcyclophosphate has also passed the United States China's FDA certification, and registration in India, Taiwan and the European Union and other places, Changzhou Binjiang economic development zone is one of the few enterprises with GMP and FDA certificates The company's products are exported to more than 30 countries and regions, with sales revenue of 53 million yuan in 2013 and 86 million yuan in 2014 It is estimated that the sales in 2015 will reach 130 million yuan, with an annual growth of more than 50%.